Design and validation of a histological scoring system for nonalcoholic fatty liver disease
- PMID: 15915461
- DOI: 10.1002/hep.20701
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."
Comment in
-
Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?Hepatology. 2011 Jun;53(6):2142-3; author reply 2143. doi: 10.1002/hep.24322. Hepatology. 2011. PMID: 21618266 No abstract available.
Similar articles
-
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease.J Clin Gastroenterol. 2011 Jan;45(1):55-8. doi: 10.1097/MCG.0b013e3181dd1348. J Clin Gastroenterol. 2011. PMID: 20505526 Free PMC article.
-
Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.Am J Gastroenterol. 2010 Sep;105(9):2093-102. doi: 10.1038/ajg.2010.152. Epub 2010 Apr 6. Am J Gastroenterol. 2010. PMID: 20372110 Free PMC article.
-
Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.J Gastroenterol Hepatol. 2022 Jun;37(6):1131-1138. doi: 10.1111/jgh.15843. Epub 2022 Apr 6. J Gastroenterol Hepatol. 2022. PMID: 35362158
-
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. World J Gastroenterol. 2014. PMID: 25400438 Free PMC article. Review.
-
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462. Int J Mol Sci. 2024. PMID: 39126031 Free PMC article. Review.
Cited by
-
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.J Gastroenterol. 2016 Feb;51(2):162-72. doi: 10.1007/s00535-015-1104-x. Epub 2015 Jul 21. J Gastroenterol. 2016. PMID: 26190501
-
Vitamin D Status and Steatohepatitis in Obese Diabetic and Non-Diabetic Patients.J Clin Med. 2022 Sep 18;11(18):5482. doi: 10.3390/jcm11185482. J Clin Med. 2022. PMID: 36143129 Free PMC article.
-
Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis.Front Pharmacol. 2021 Apr 23;12:622040. doi: 10.3389/fphar.2021.622040. eCollection 2021. Front Pharmacol. 2021. PMID: 33967756 Free PMC article.
-
B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease.Hepatol Int. 2013 Jun;7(2):539-47. doi: 10.1007/s12072-012-9345-8. Epub 2012 Feb 9. Hepatol Int. 2013. PMID: 26201785
-
Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare.Gastroenterol Res Pract. 2020 Jul 13;2020:7347068. doi: 10.1155/2020/7347068. eCollection 2020. Gastroenterol Res Pract. 2020. PMID: 32765601 Free PMC article.
Publication types
MeSH terms
Grants and funding
- N01HR761019/HR/NHLBI NIH HHS/United States
- 1U01DK061728/DK/NIDDK NIH HHS/United States
- 5U01DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- 1U01DK061738/DK/NIDDK NIH HHS/United States
- 1U01DK061734/DK/NIDDK NIH HHS/United States
- 1U01DK061731/DK/NIDDK NIH HHS/United States
- 7U01DK061713/DK/NIDDK NIH HHS/United States
- 1U01DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- 1U01DK061718/DK/NIDDK NIH HHS/United States
- 1U01DK061732/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources